Navigation Links
A prognostic and predictive biomarker for nonsmall cell lung cancer
Date:6/1/2010

The era of one-size-fits-all medicine will eventually be history; after all it is no news that drugs and treatments do not work the same for everyone. For patients with nonsmall cell lung cancer (NSCLC), a lung cancer that kills approximately 1 million people annually, the treatment currently available is basically the same for all patients, despite the fact that some patients may respond to treatment while others may not. New biological markers and prognostic tools are urgently needed to help doctors decide on the best course of action for each NSCLC patient. It now appears that this reality is not years away, at least for NSCLC treatment.

Currently, NSCL prognosis is made based on patient's general performance and tumor staging. Still, doctors do not know which patients with NSCLC may survive for only 10 months and which for 5 years. Now, a study published ahead of print in the journal Cancer ("CFL1 expression levels as a prognostic and drug resistance marker in nonsmall cell lung cancer", DOI 10.1002/cncr.25125) presents strong evidence that a protein called cofilin (CFL1) may help doctors in determining patient prognosis and in identifying those in need of a more aggressive treatment. The study also indicates that based on this protein, doctors may decide which drugs to use, and which to avoid, when treating NSCL patients. The possibility of doctors knowing before prescription which drugs are likely to work best for each patient represents a great advance in cancer treatment.

The group led by Dr. Fbio Klamt, a researcher at the Department of Biochemistry at the Federal University of Rio Grande do Sul, Brazil found that cofilin levels can be used to indicate which patients in the early stages of the disease have a good prognosis and which do not. When studying a large collection of NSCL cancer samples, the researchers found that the biopsies in which high levels of cofilin were found were from patients who had survived for shorter periods than those from patients with lower expression of the protein.

Besides the correlation found between cofilin and patient survival, the group also investigated whether cofilin levels could provide any clues on tumor aggressiveness. According to Dr. Klamt, "cofilin is a protein associated with cell mobility. We know that poor prognosis correlates with the ability of cells to move to generate metastasis. Thus, it seemed only reasonable that cells with lower levels of this protein would be less aggressive while higher levels would provide a more aggressive behavior." Indeed, the group tested six human cell lines of 3 major types of NSCLC and found that the types with higher levels of cofilin presented a greater potential to invade other sites in the body, which indicates a more aggressive behavior. "For patients," explains Dr. Klamt, "this finding indicates that lower levels of cofilin translate into lower chances to develop metastasis, which ultimately leads to a better prognosis."

The group also found that high levels of cofilin correlate with resistance to certain anticancer drugs, especially cisplatin and carboplatin, which have long been used for treating NSCLC. Cisplatin-based chemotherapy is the standard first-line treatment for patients at an early stage and with good performance. Nevertheless, only some will respond to this treatment. Now cofilin levels may be used to distinguish between responders and non-responders. This new finding may have great impact on survival rates, as potential non-responders may benefit from different treatment options that would not be available otherwise.


'/>"/>

Contact: Marcia Triunfol
mtriunfol@gmail.com
55-248-142-0202
Publicase Comunicao Cientfica
Source:Eurekalert

Related medicine news :

1. "IPGDx, LLC Announces The Continued Validation Of Its Patented Technology For The Assessment Of Prognosis; PrognostiCheck" Getting the New Information to Patients and Do
2. Springer publishes new journal in predictive, preventive and personalized medicine
3. The Simple and Revolutionary Power to OUTSMART YOUR GENES Out April 6th -- Predictive Medicine Pioneer Dr. Brandon Colby Releases Book
4. Existence Genetics is Pioneering the Field of Predictive Medicine - Nexus Technologies Critical in Understanding and Preventing Deadly Disease
5. Michael J. Fox Foundation Awards $2.8 Million to Drive Development of Parkinsons Disease Biomarker Pipeline
6. Biomarker could help doctors tailor treatment for rheumatoid arthritis
7. TGen analysis identifies biomarkers for diabetic kidney failure
8. Researchers find biomarkers in saliva for detection of early-stage pancreatic cancer
9. Personalizing cancer: Creating biomarkers from tumor DNA
10. Damaged protein identified as early diagnostic biomarker for Alzheimers disease in healthy adults
11. Reliable biomarkers needed for early detection of liver cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... ... May 02, 2016 , ... ... will be held at the Bellagio Hotel in Las Vegas, NV from October ... (NASW) will be co-hosting the event. , This year’s conference will offer ...
(Date:5/2/2016)... ... May 02, 2016 , ... ... urgent care facilities designed to automate and improve the rapid diagnosis, triage and ... is demonstrating their platform, application, and mobile experience for the first time at ...
(Date:5/2/2016)... Louis, MO (PRWEB) , ... May 02, 2016 ... ... Inc., a division of Permobil, recently completed two groundbreaking studies that determined that ... and mattresses – are critical in the prevention of pressure injuries, which are ...
(Date:5/2/2016)... PARSIPPANY, N.J. (PRWEB) , ... May 02, 2016 ... ... - Healthcare Research & Analytics EVP and GM Jim Callandrillo and Duane ... during the 55th Annual Pharmaceutical Business Intelligence and Research Group (PBIRG) General ...
(Date:5/2/2016)... ... May 02, 2016 , ... Dr. Jonathan Kulbersh of Carolina Facial Plastics isn’t surprised that ... on the list of “ 5 US Cities with the Highest Plastic Rates .” ... Miami. The results were calculated using a survey by RealSelf and combining ...
Breaking Medicine News(10 mins):
(Date:5/2/2016)... , May 2, 2016 ... to reach USD 11.1 billion by 2024, according ... Research, Inc. Major drivers of the sonography market ... areas and government recommendations for periodic ultrasound screenings ...      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) ...
(Date:4/29/2016)... COUNTY, Calif. , April 29, 2016 /PRNewswire/ ... industry is projected to shift from systems dependent ... replace all types of modality CRT Medical monitors ... Although there are a host of foreseeable benefits ... serious concern; will existing modalities have to be ...
(Date:4/29/2016)... ReportsnReports.com adds "Pulmonary Arterial ... report that provides an overview of the PAH ... stages, therapeutics assessment by drug target, mechanism of ... type, along with latest updates, and featured news ... involved in the therapeutic development for Pulmonary Arterial ...
Breaking Medicine Technology: